National Pharmaceutical Council published a guide explaining the risks of Upper Payment Limit (UPL) implementation, what's at stake, and the current landscape.
Published
Signal category
Research & Knowledge
Quote
“Our guide explains the risks of UPLs, what’s at stake, and the current landscape.”
— National Pharmaceutical Council team
Company
National Pharmaceutical Council
Policy-relevant research since 1953
- Industry
- Pharmaceutical Manufacturing
- Location
- Washington, US
- Company size
- 39 employees
NPC serves patients and society with policy-relevant research on the value of patient access to innovative medicines and the importance of scientific advancement. We envision a world where advances in medicine are accessible to patients, valued by society, and sustainably reimbursed by payers to ensure continued innovation. We provide the evidence to bolster the case for the value of innovation through our policy-relevant research. NPC informs policy discussions in the media, in Congressional testimony, and through leading voices sharing our research about the future of innovative medicine and patient access.
Founded 1953